<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="55003711"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<note type="other">Probe Report<lb/></note>

	<docTitle>
	<titlePart>Title: Identification of activators for the M2 isoform of human pyruvate kinase Version 3<lb/></titlePart>
	</docTitle>

	<byline>
	<docAuthor>Authors: Matthew B. Boxer,<lb/> a<lb/> Jian-kang Jiang,<lb/> a<lb/> Matthew G. Vander Heiden,<lb/> b,c<lb/> Min Shen,<lb/> a<lb/> Henrike Veith,<lb/> a<lb/> Lewis C. Cantley,<lb/> d,e<lb/> Craig J. Thomas<lb/> a<lb/> </docAuthor>
	</byline>

	<byline>
	<affiliation>a)<lb/> NIH Chemical Genomics Center, National Human Genome Research Institute, National<lb/> Institutes of Health,</affiliation>
	</byline>

	<address>9800 Medical Center Drive, MSC 3370 Bethesda, Maryland 20850,<lb/></address>

	<byline>
	<affiliation>b)<lb/> Koch<lb/> Institute at MIT,</affiliation>
	</byline>

	<address>Cambridge, MA 02139, USA<lb/></address>

	<byline>
	<note type="other">c)<lb/></note>
	</byline>

	<byline>
	<affiliation>Dana Farber Cancer Institute,</affiliation>
	</byline>

	<address>Boston,<lb/> Massachusetts 02115,<lb/></address>

	<byline>
	<note type="other">d)<lb/></note>
	</byline>

	<byline>
	<affiliation>Department of Systems Biology, Harvard Medical School,</affiliation>
	</byline>

	<address>Boston,<lb/> Massachusetts 02115, and<lb/></address>

	<note type="other">e)<lb/></note>

	<byline>
	<affiliation>Division of Signal Transduction, Beth Israel Deaconess Medical<lb/> Center,</affiliation>
	</byline>

	<address>Boston, Massachusetts 02115<lb/></address>

	<note type="other">Assigned Assay Grant #: R03 MH085679<lb/> Screening Center Name &amp; PI: NIH Chemical Genomics Center &amp; Dr. Christopher P. Austin<lb/> Chemistry Center Name &amp; PI: NIH Chemical Genomics Center &amp; Dr. Christopher P. Austin<lb/> Assay Submitter &amp; Institution: Dr. Matthew George Vander Heiden, Harvard<lb/> PubChem Summary Bioassay Identifier (AID): 2095<lb/></note>

	<div type="abstract">Abstract:<lb/> The expression of human pyruvate kinase M2 (hPK-M2) in cancer cells appears to be critical for tumor<lb/> cell growth and proliferation in vivo. Because the PK-M2 isoform is expressed in all cancer cells studied,<lb/> it represents a target for drug development that could potentially enable tumor cells to return to a normal<lb/> state of metabolism. If this novel strategy for targeting malignancy were successful, it would be<lb/> applicable to diverse types of cancer. The probes ML203(CID-44543605), ML202 (CID-44246498), and<lb/> ML170 (CID-4547230) are members of a series of highly specific allosteric activators for the tumor-<lb/>specific isoform of human pyruvate kinase (M2 isoform). All three probes affect the cooperativity of<lb/> phosphoenolpyruvate (PEP) binding, with little affect on adenosine diphosphate (ADP) binding, in a<lb/> manner similar to FBP.</div>

		</front>
	</text>
</tei>
